Evidence map›Paper›PMID 39668275›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer.

Oraianthi Fiste, Evangelos Mavrothalassitis, Alexandros Kokkalis, Maximilian Anagnostakis, Georgia Gomatou, Athanasios Kontogiannis, Dimitra Karaviti, Eleftheria Karaviti, Nikolaos Konstantinos Syrigos, Athanasios Kotsakis and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Oraianthi FisteOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece. ofiste@med.uoa.gr.ORCID http://orcid.org/0000-0002-7106-4162
Evangelos MavrothalassitisOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Alexandros KokkalisDepartment of Medical Oncology, University Hospital of Larissa, 41334, Larissa, Greece.
Maximilian AnagnostakisOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Georgia GomatouOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Athanasios KontogiannisOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Dimitra KaravitiOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Eleftheria KaravitiOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Nikolaos Konstantinos SyrigosOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.
Athanasios KotsakisDepartment of Medical Oncology, University Hospital of Larissa, 41334, Larissa, Greece.
Elias Alexandros KotteasOncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor's biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified.

methodsThe present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR.

resultsDespite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts.

conclusionIn the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process.

Indexed as

Biomarkers, TumorBreast NeoplasmsInflammationLymphocytesNeutrophilsAdultAgedBlood PlateletsFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingPrognosisRetrospective StudiesBiomarkers, TumorBiomarkersBreast cancerLymphocytesNeoadjuvant therapyNeutrophilsPathologic complete responsePlatelets

Identifiers

PMID39668275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.